Autolus Therapeutics
AUTL
65 hedge funds and large institutions have $195M invested in Autolus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 14 closing their positions.
454% more call options, than puts
Call options by funds: $72K | Put options by funds: $13K
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
3.85% less ownership
Funds ownership: 65.13% → 61.28% (-3.8%)
5% less capital invested
Capital invested by funds: $206M → $195M (-$10.4M)
10% less funds holding
Funds holding: 72 → 65 (-7)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$3.32M |
| 2 |
BlackRock
New York
|
+$925K |
| 3 |
Millennium Management
New York
|
+$458K |
| 4 |
IAM
Innovis Asset Management
Chicago,
Illinois
|
+$247K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.44M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.35M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$1.19M |
| 4 |
AC
Armistice Capital
New York
|
-$1.08M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$950K |
AUTL Hedge Fund Activity: Q1 2023 in Review
65 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2023, worth a combined $195M — down 5.1% from $206M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AUTL and 8 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 21 added.
The largest buyer was TFG Asset Management, adding an estimated $3.32M. The largest seller was Alyeska Investment Group, cutting an estimated $2.44M.
- 65 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2023, down from 72 in Q4 2022.
- Funds reported $195M of Autolus Therapeutics stock for Q1 2023, down 5.1% quarter-over-quarter.
- 8 funds opened new Autolus Therapeutics positions in Q1 2023 and 14 closed out, a net change of -6 holders.
- The largest Autolus Therapeutics buyer in Q1 2023 was TFG Asset Management, an estimated $3.32M added.
- The largest Autolus Therapeutics seller in Q1 2023 was Alyeska Investment Group, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2023.